Asosiy kontentga oʻtish
Maqola

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKAndrew J.S. FurnessCancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UKRachel RosenthalCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKSofie RamskovSection for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, DenmarkRikke LyngaaSection for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, DenmarkSunil Kumar SainiSection for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, DenmarkMariam Jamal‐HanjaniCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKGareth A. WilsonCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKNicolai J. BirkbakCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKCrispin T. HileyUniversity College LondonThomas B.K. WatkinsUniversity College LondonSeema ShafiUniversity College LondonNirupa MurugaesuCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKRichard MitterThe Francis Crick Institute, London WC2A 3LY, UKAyse U. AkarcaUniversity College LondonJoseph LinaresCRUK Lung Cancer Centre of ExcellenceTeresa MarafiotiUniversity College LondonJake Y. HenryUniversity College LondonEliezer M. Van AllenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USADiana MiaoBroad Institute of MIT and Harvard, Cambridge, MA 02142, USABastian SchillingDepartment of Dermatology, University Hospital, University Duisburg–Essen, 45147 Essen, GermanyDirk SchadendorfUniversity of Duisburg-EssenLevi A. GarrawayBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAVladimir MakarovHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USANaiyer A. RizviHematology/Oncology Division, 177 Fort Washington Avenue, Columbia University, New York, NY 10032, USAAlexandra SnyderWeill Cornell Medical College, New York, NY 10065, USAMatthew D. HellmannDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USATaha MerghoubDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USAJedd D. WolchokLudwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USASachet A. ShuklaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USACatherine J. WuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USAKarl S. PeggsCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UKTimothy A. ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USASine Reker HadrupSection for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, DenmarkSergio A. QuezadaUniversity College LondonCharles SwantonThe Francis Crick Institute, London WC2A 3LY, UK
2016en
ABI

Annotatsiya

As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8(+)tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non-small cell lung cancer and expressed high levels of PD-1. Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. T cells recognizing clonal neoantigens were detectable in patients with durable clinical benefit. Cytotoxic chemotherapy-induced subclonal neoantigens, contributing to an increased mutational load, were enriched in certain poor responders. These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba